• +1-646-491-9876
    • +91-20-67278686

    Search

    Diphtheria Pipeline Review H1 2017

    Diphtheria Pipeline Review H1 2017

    • Report Code ID: RW0001799290
    • Category Pharmaceuticals
    • No. of Pages 68
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Diphtheria - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diphtheria - Pipeline Review, H1 2017, provides an overview of the Diphtheria (Infectious Disease) pipeline landscape.

    Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Diphtheria - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diphtheria (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Diphtheria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Diphtheria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 9, 4, 5, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 2 molecules, respectively.

    Diphtheria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Diphtheria (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Diphtheria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Diphtheria (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Diphtheria (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Diphtheria (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Diphtheria (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Diphtheria (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Diphtheria - Overview
    Diphtheria - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Diphtheria - Therapeutics Assessment
    Assessment by Target
    Assessment by Route of Administration
    Assessment by Molecule Type
    Diphtheria - Companies Involved in Therapeutics Development
    Beijing Minhai Biotechnology Co Ltd
    Biological E Ltd
    Boryung Pharmaceutical Co Ltd
    Daiichi Sankyo Company Ltd
    GlaxoSmithKline Plc
    Green Cross Corp
    Indian Immunologicals Ltd
    Kaketsuken KK
    LG Chem, Ltd.
    Prometheon Pharma LLC
    Sanofi
    Sanofi Pasteur SA
    Serum Institute of India Ltd
    Shantha Biotechnics Ltd
    Zydus Cadila Healthcare Ltd
    Diphtheria - Drug Profiles
    (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + tetanus + pertussis (acellular) ) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BK-1310 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BVN-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    diphtheria vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DTaP-IPV-HB-PRPT - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GC-1107 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GC-3111A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KD-370 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LBVD - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VN-0105 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Diphtheria - Dormant Projects
    Diphtheria - Discontinued Products
    Diphtheria - Product Development Milestones
    Featured News & Press Releases
    Nov 24, 2014: CanSinotech submitted CTA of "Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed" to CFDA
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Diphtheria, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Diphtheria - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
    Diphtheria - Pipeline by Biological E Ltd, H1 2017
    Diphtheria - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017
    Diphtheria - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Diphtheria - Pipeline by GlaxoSmithKline Plc, H1 2017
    Diphtheria - Pipeline by Green Cross Corp, H1 2017
    Diphtheria - Pipeline by Indian Immunologicals Ltd, H1 2017
    Diphtheria - Pipeline by Kaketsuken KK, H1 2017
    Diphtheria - Pipeline by LG Chem, Ltd., H1 2017
    Diphtheria - Pipeline by Prometheon Pharma LLC, H1 2017
    Diphtheria - Pipeline by Sanofi, H1 2017
    Diphtheria - Pipeline by Sanofi Pasteur SA, H1 2017
    Diphtheria - Pipeline by Serum Institute of India Ltd, H1 2017
    Diphtheria - Pipeline by Shantha Biotechnics Ltd, H1 2017
    Diphtheria - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
    Diphtheria - Dormant Projects, H1 2017
    Diphtheria - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Diphtheria - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Diphtheria, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Beijing Minhai Biotechnology Co Ltd
    Biological E Ltd
    Boryung Pharmaceutical Co Ltd
    Daiichi Sankyo Company Ltd
    GlaxoSmithKline Plc
    Green Cross Corp
    Indian Immunologicals Ltd
    Kaketsuken KK
    LG Chem, Ltd.
    Prometheon Pharma LLC
    Sanofi
    Sanofi Pasteur SA
    Serum Institute of India Ltd
    Shantha Biotechnics Ltd
    Zydus Cadila Healthcare Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//diphtheria-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//diphtheria-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//diphtheria-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments